Get the Stockscreener App
3.14
1.57%
-0.05
After Hours:
3.10
-0.04
-1.27%
Ac Immune Sa stock is traded at $3.14, with a volume of 213.61K.
It is down -1.57% in the last 24 hours and up +4.15% over the past month.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
See More
Previous Close:
$3.19
Open:
$3.1
24h Volume:
213.61K
Relative Volume:
0.71
Market Cap:
$319.57M
Revenue:
$4.28M
Net Income/Loss:
$-84.59M
P/E Ratio:
-3.7399
EPS:
-0.8396
Net Cash Flow:
$-87.79M
1W Performance:
-2.18%
1M Performance:
+4.15%
6M Performance:
+2.28%
1Y Performance:
+107.95%
1-Day Range:
$3.05
$3.195
1-Week Range:
$3.05
$3.49
52-Week Range:
$1.45
$4.00
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
3.14 | 324.66M | 4.28M | -84.59M | -87.79M | -0.8396 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-31-24 | Initiated | BTIG Research | Buy |
| Feb-01-19 | Downgrade | UBS | Buy → Neutral |
| Jan-04-19 | Initiated | UBS | Buy |
| Apr-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-23-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-18-16 | Initiated | Credit Suisse | Outperform |
| Oct-18-16 | Initiated | Jefferies | Buy |
| Oct-18-16 | Initiated | Leerink Partners | Outperform |
View All
Ac Immune Sa Stock (ACIU) Latest News
AC Immune secures CHF 10 million from Lilly to advance Alzheimer’s therapy - Greater Geneva Bern area
AC Immune revises collaboration with Eli Lilly on tau-targeting Alzheimer’s therapy - MSN
ACIU stock rallies 16.3% in a week: Here's what you need to know - MSN
Leerink Says AC Immune (ACIU) Eli Lilly Tau Program Amendment Is Great News - Insider Monkey
5 Best Strong Buy European Stocks to Invest In - Insider Monkey
Resistance Check: Can AC Immune SA weather a recessionQuarterly Trade Review & Smart Investment Allocation Tips - baoquankhu1.vn
ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know - TradingView
Can AC Immune SA reach resistance levels soonWeekly Trade Summary & Safe Entry Zone Identification - baoquankhu1.vn
Fed Watch: Will AC Immune SA stock hit new highs in YEARTrade Entry Report & Low Risk Investment Opportunities - baoquankhu1.vn
April 2026's Most Promising Penny Stocks - Yahoo Finance
Leerink reiterates AC Immune stock rating on Lilly deal amendment By Investing.com - Investing.com Canada
Why AC Immune Stock Zoomed Almost 15% Higher Today - Yahoo Finance
Leerink reiterates AC Immune stock rating on Lilly deal amendment - Investing.com
AC Immune stock surges on amended Lilly collaboration deal - Investing.com
AC Immune stock surges on amended Lilly collaboration deal By Investing.com - Investing.com South Africa
AC Immune amends license and collaboration deal with Lilly - The Pharma Letter
AC Immune rises after amending licensing deal with Lilly - Seeking Alpha
AC Immune, Lilly Amend Morphomer Tau Alliance - Contract Pharma
AC Immune amends Lilly collaboration, plans tau drug studies By Investing.com - Investing.com South Africa
AC Immune Secures Amended Tau Drug Collaboration with Lilly, Adds CHF 10 Million Upfront - TipRanks
According to the latest revised agreement terms, AC Immune SA will receive a total upfront payment of 10 million Swiss francs. - Bitget
AC Immune (NASDAQ: ACIU) amends Lilly Tau deal with CHF 10m upfront - Stock Titan
AC Immune amends Lilly collaboration, plans tau drug studies - Investing.com
AC Immune announces amendment to Morphomer® tau license and collaboration agreement with Lilly - marketscreener.com
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly - The Manila Times
ACIU Technical Analysis & Stock Price Forecast - Intellectia AI
ACIU Stock Price, Quote & Chart | AC IMMUNE SA (NASDAQ:ACIU) - ChartMill
AC Immune (ACIU) director Zuegel reports options and RSU-based share stakes - Stock Titan
Exit Recap: Can AC Immune SA deliver consistent EPS growthWeekly Trend Report & Smart Investment Allocation Tips - baoquankhu1.vn
Is AC Immune (ACIU) outperforming other medical stocks this year? - MSN
Ideas Watch: What is the long term forecast for AC Immune SA stockRate Cut & Entry and Exit Point Strategies - baoquankhu1.vn
ACIU SEC FilingsAC Immune 10-K, 10-Q, 8-K Forms - Stock Titan
AC Immune Posts 2025 Results, Sharpens Pipeline Focus and Extends Cash Runway to 2027 - TipRanks
AC Immune FY 2025 Results: Eyeing ACI-7104 Catalysts - seekingalpha.com
Trading Recap: Will AC Immune SA stock hit new highs in YEAR2026 Investor Takeaways & Fast Gain Swing Alerts - baoquankhu1.vn
AC Immune (ACIU) COO Piergiorgio Donati reports shares and long-dated options - Stock Titan
AC Immune shows first brain images of TDP-43 pathology in trial - Investing.com India
ACIU Unveils Promising Phase 1 Data for TDP-43 PET Imaging - GuruFocus
AC Immune Presents First In vivo Images of Brain TDP-43 - GlobeNewswire
Aug Volume: Does AC Immune SA outperform in volatile markets2026 Price Momentum & Growth Oriented Trading Recommendations - baoquankhu1.vn
AC Immune (ACIU) CFO discloses common shares, RSUs and option grants - Stock Titan
AC Immune (NASDAQ: ACIU) director Monika Buetler details initial share and option holdings - Stock Titan
AC Immune (NASDAQ: ACIU) director reports initial Form 3 holdings - Stock Titan
[Form 3] AC Immune SA Initial Statement of Beneficial Ownership - Stock Titan
AC Immune (ACIU) CEO discloses equity and option holdings - Stock Titan
AC Immune (ACIU) director June Carl Howard details share and option stakes - Stock Titan
AC Immune (ACIU) Upgraded to Buy: Here's Why - Yahoo Finance
Is AC Immune (ACIU) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Ac Immune Sa Stock (ACIU) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):